Komori
Revision of earnings forecasts5187CREATE MEDIC CO.,LTD.Electrical Equipment and Precision Instruments

Notice Regarding Differences Between Second-Quarter (Interim-Period) Forecasts and Actual Results and Revisions to Full-Year Consolidated Financial Forecasts

For the interim period, net sales exceeded the forecast, while operating income, ordinary income and interim net income fell below the forecast. For the full year, the net sales forecast was left unchanged, while the forecasts for operating income, ordinary income and net income were revised downward.

Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-300
¥ million
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending December 2026 · Cumulative second quarter (interim period) and full yearPrevious forecast published 13 February 2026 ("Summary of Financial Results for the Fiscal Year Ended December 2025")
Net SalesCumulative second-quarter results6,630→—million
—
Net SalesFull year13,960→13,960million
0.0%
Operating profitCumulative second-quarter results510→—million
—
Operating profitFull year1,060→760million
-28.3%
Ordinary incomeCumulative second-quarter results510→—million
—
Ordinary incomeFull year1,070→800million
-25.2%
Profit attributable to owners of the parentSix months ending June (interim net income)357→—million
—
Profit attributable to owners of the parentFull year (net income)750→—million
—
Net income per shareSix months ending June (interim net income)42.58→—yen and sen
—
Net income per shareFull year89.44→68.9yen and sen
-23.0%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

Net sales for the interim period exceeded the previous forecast, mainly because domestic sales remained solid. However, profit margins declined due to the impact of bids under centralized purchasing in China and the rapid depreciation of the yen, causing operating income, ordinary income and interim net income attributable to owners of the parent to fall below the forecast. Accordingly, the full-year profit forecasts were revised downward.

Previous-period resultsCumulative second quarter (interim period for the fiscal year ended December 2025) Net Sales Value ¥6,564 million / Operating profit Value ¥548 million / Ordinary income Value ¥525 million / Interim net income attributable to owners of the parent Value ¥412 million / Interim net income per share Value 48.35 yen and sen / Full year (fiscal year ended December 2025) Net Sales Value ¥13,617 million / Operating profit Value ¥1,005 million / Ordinary income Value ¥988 million / Profit attributable to owners of the parent Value ¥713 million / Net income per share Value 84.25 yen and sen
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net SalesCumulative second-quarter results 6,630 / Full year 13,960 → Cumulative second-quarter actual results 6,932 / Full year 13,960(Cumulative second-quarter results 4.6% / Full year 0.0%)
Operating profitCumulative second-quarter results 510 / Full year 1,060 → Cumulative second-quarter actual results 336 / Full year 760(Cumulative second-quarter results △34.0% / Full year △28.3%)
Ordinary incomeCumulative second-quarter results 510 / Full year 1,070 → Cumulative second-quarter actual results 398 / Full year 800(Cumulative second-quarter results △21.9% / Full year △25.2%)
Profit attributable to owners of the parentSix months ending June (interim net income) 357 / Full year (net income) 750 → Cumulative second quarter (actual interim net income) 260 / Full year (current revised forecast: net income) 560(Cumulative second-quarter results △27.1% / Full year △25.3%)
Net income per shareSix months ending June (interim net income) 42.58 / Full year 89.44 → Cumulative second-quarter actual results 31.63 / Full year 68.90
Fiscal Period CoveredFiscal year ending December 2026
Period CoveredCumulative second quarter (interim period) and full year
Publication date of previous forecast13 February 2026 ("Summary of Financial Results for the Fiscal Year Ended December 2025")
Previous-period resultsCumulative second quarter (interim period for the fiscal year ended December 2025) Net Sales Value ¥6,564 million / Operating profit Value ¥548 million / Ordinary income Value ¥525 million / Interim net income attributable to owners of the parent Value ¥412 million / Interim net income per share Value 48.35 yen and sen / Full year (fiscal year ended December 2025) Net Sales Value ¥13,617 million / Operating profit Value ¥1,005 million / Ordinary income Value ¥988 million / Profit attributable to owners of the parent Value ¥713 million / Net income per share Value 84.25 yen and sen
Reason for the revisionNet sales for the interim period exceeded the previous forecast, mainly because domestic sales remained solid. However, profit margins declined due to the impact of bids under centralized purchasing in China and the rapid depreciation of the yen, causing operating income, ordinary income and interim net income attributable to owners of the parent to fall below the forecast. Accordingly, the full-year profit forecasts were revised downward.
Consolidated / non-consolidatedConsolidated
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Although domestic sales exceeded the forecast on solid demand, profit margins declined due to the impact of bids under centralized purchasing in China and the rapid depreciation of the yen. Accordingly, the full-year profit forecasts were revised downward.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Differences Between Second-Quarter (Interim-Period) Forecasts and Actual Results and Revisions to Full-Year Consolidated Financial Forecasts | CREATE MEDIC CO.,LTD. (5187) timely disclosure | Komori